Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 26-50 of 218 citing articles:

Obesity and the kidney: mechanistic links and therapeutic advances
Kevin Yau, Rachel Kuah, David Z.I. Cherney, et al.
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 6, pp. 321-335
Closed Access | Times Cited: 28
Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5/NR4a1 axis
Yulan Ma, Chun‐Yan Kong, Zhen Guo, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 23
Effectiveness and safety of drugs for obesity
Kristina H. Lewis, Caroline E Sloan, Daniel H. Bessesen, et al.
BMJ (2024), pp. e072686-e072686
Open Access | Times Cited: 22
Pharmacotherapy for obesity: moving towards efficacy improvement
Walmir Coutinho, Bruno Halpern
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 18
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Jens J. Holst
Nature Metabolism (2024) Vol. 6, Iss. 10, pp. 1866-1885
Open Access | Times Cited: 18
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
Nasreen Alfaris, Stephanie W. Waldrop, Veronica Johnson, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102782-102782
Open Access | Times Cited: 16
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Journal of Preventive Cardiology (2024)
Open Access | Times Cited: 16
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Lauren A. Jones, Daniel I. Brierley
Endocrinology (2025)
Open Access | Times Cited: 2
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angeliki M. Angelidi, Matthew J. Belanger, Alexander Kokkinos, et al.
Endocrine Reviews (2021) Vol. 43, Iss. 3, pp. 507-557
Open Access | Times Cited: 79
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Mathies M. Jepsen, Mikkel Christensen
Expert Opinion on Emerging Drugs (2021) Vol. 26, Iss. 3, pp. 231-243
Closed Access | Times Cited: 70
Development of Cagrilintide, a Long-Acting Amylin Analogue
Thomas Kruse, Jakob Lerche Hansen, Kirsten Dahl, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 11183-11194
Open Access | Times Cited: 66
Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss
Berit Østergaard Christoffersen, Guillermo Sánchez‐Delgado, Linu M. John, et al.
Obesity (2022) Vol. 30, Iss. 4, pp. 841-857
Open Access | Times Cited: 64
New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications
W. Timothy Garvey
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 4, pp. e1339-e1347
Open Access | Times Cited: 62
Obesity‐related glomerulopathy: Current approaches and future perspectives
José Ignacio Martínez‐Montoro, Enrique Morales, Isabel Cornejo‐Pareja, et al.
Obesity Reviews (2022) Vol. 23, Iss. 7
Open Access | Times Cited: 60
Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
Núria Vilarrasa, Patricia San José, Miguel A. Rubio, et al.
Diabetes Metabolic Syndrome and Obesity (2021) Vol. Volume 14, pp. 2807-2827
Open Access | Times Cited: 58
What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review
Deborah B. Horn, Jaime P. Almandoz, Michelle Look
Postgraduate Medicine (2022) Vol. 134, Iss. 4, pp. 359-375
Open Access | Times Cited: 49
A structural basis for amylin receptor phenotype
Jianjun Cao, Matthew J. Belousoff, Yi-Lynn Liang, et al.
Science (2022) Vol. 375, Iss. 6587
Closed Access | Times Cited: 45
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, et al.
Trends in Endocrinology and Metabolism (2022) Vol. 33, Iss. 6, pp. 424-442
Closed Access | Times Cited: 45
New therapies for obesity
Dimitris Papamargaritis, Carel W. le Roux, Jens J. Holst, et al.
Cardiovascular Research (2022) Vol. 119, Iss. 18, pp. 2825-2842
Open Access | Times Cited: 41
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
Angelica Artasensi, Angelica Mazzolari, Alessandro Pedretti, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3094-3094
Open Access | Times Cited: 35
Current and future pharmacotherapies for obesity in children and adolescents
Aaron S. Kelly
Nature Reviews Endocrinology (2023) Vol. 19, Iss. 9, pp. 534-541
Closed Access | Times Cited: 28
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Christine R. Andreasen, Andreas Andersen, Tina Vilsbøll
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1846-1858
Open Access | Times Cited: 26
Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety
Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjær Jensen, et al.
Obesity Reviews (2024) Vol. 25, Iss. 5
Open Access | Times Cited: 14
Clinical Pharmacokinetics of Semaglutide: A Systematic Review
Xi‐Ding Yang, Xi‐Ding Yang
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 2555-2570
Open Access | Times Cited: 14
Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity
Stjepan Eržen, Gašper Tonin, Dubravka Jurišić‐Eržen, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1517-1517
Open Access | Times Cited: 13

Scroll to top